Supporting the

Neuroendocrine Cancer Community

Merkel Cell Carcinoma (MCC) Skin Cancer

Merkel Cell Carcinoma (MCC) Skin Cancer

Neuroendocrine Cancer UK is supporting Skin Cancer Awareness Month. Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause of...
Merkel Cell Carcinoma (MCC) Skin Cancer

Merkel Cell Carcinoma (MCC)

Neuroendocrine Cancer UK is supporting Skin Cancer Awareness Month.   Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause...
NICE approves Avelumab

NICE approves Avelumab

21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC.  Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults...
NICE launches their 2021-2026 strategy

NICE launches their 2021-2026 strategy

Yesterday, Monday April 19th, NICE launched their 2021-2026 strategy ” a vision for the future”.   According to NICE – Public and patients will see:   – An interactive guideline structure that facilitates links to the underpinning evidence and...